# Candel Therapeutics, Inc.: financial statements, quarterly

CADL · Nasdaq · CIK 1841387 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cadl.md) · [Financials](/companies/cadl/financials.md) · [Filings](/companies/cadl/filings.md) · [Insiders](/companies/cadl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cadl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [5.8](/filings/0000950170-24-126767.md) | [7.3 d](/filings/0000950170-25-038803.md) | [4.1](/filings/0000950170-25-069833.md) | [5.0](/filings/0000950170-25-108450.md) | [5.4](/filings/0001193125-25-279086.md) | [4.8 d](/filings/0001193125-26-103134.md) | [4.0](/filings/0001193125-26-222904.md) | [7.0](/filings/0001193125-26-347980.md) | [8.5](/filings/0001193125-25-279086.md) | [11.0 d](/filings/0001193125-26-103134.md) | [9.8](/filings/0001193125-26-222904.md) | [19.8](/filings/0001193125-26-347980.md) |
| Operating income | $m | [(8.9)](/filings/0000950170-24-126767.md) | [(10.3) d](/filings/0000950170-25-038803.md) | [(7.9)](/filings/0000950170-25-069833.md) | [(8.6)](/filings/0000950170-25-108450.md) | [(8.8)](/filings/0001193125-25-279086.md) | [(8.1) d](/filings/0001193125-26-103134.md) | [(8.1)](/filings/0001193125-26-222904.md) | [(11.2)](/filings/0001193125-26-347980.md) | [(13.2)](/filings/0001193125-25-279086.md) | [(15.8) d](/filings/0001193125-26-103134.md) | [(16.3)](/filings/0001193125-26-222904.md) | [(26.7)](/filings/0001193125-26-347980.md) |
| Interest expense | $m | [0.7](/filings/0000950170-24-126767.md) | [(4.5) d](/filings/0000950170-25-038803.md) | [0.6](/filings/0000950170-25-069833.md) | [0.6](/filings/0000950170-25-108450.md) | [0.5](/filings/0001193125-25-279086.md) | [0.4 d](/filings/0001193125-26-103134.md) | [0.3](/filings/0001193125-26-222904.md) | [0.2](/filings/0001193125-26-347980.md) | [0.2](/filings/0001193125-25-279086.md) | [1.4 d](/filings/0001193125-26-103134.md) | [1.6](/filings/0001193125-26-222904.md) | [1.6](/filings/0001193125-26-347980.md) |
| Income tax | $m | [0.0 d](/filings/0000950170-23-061566.md) | [0.0 d](/filings/0000950170-25-038803.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(8.4)](/filings/0000950170-24-126767.md) | [(11.1) d](/filings/0000950170-25-038803.md) | [(8.2)](/filings/0000950170-25-069833.md) | [(22.2)](/filings/0000950170-25-108450.md) | [(10.6)](/filings/0001193125-25-279086.md) | [(14.1) d](/filings/0001193125-26-103134.md) | [7.4](/filings/0001193125-26-222904.md) | [(4.8)](/filings/0001193125-26-347980.md) | [(11.3)](/filings/0001193125-25-279086.md) | [(29.5) d](/filings/0001193125-26-103134.md) | [(8.9)](/filings/0001193125-26-222904.md) | [(38.9)](/filings/0001193125-26-347980.md) |
| Diluted EPS | $ per share | [(0.29)](/filings/0000950170-24-126767.md) | not reported | [(0.28)](/filings/0000950170-25-069833.md) | [(0.74)](/filings/0000950170-25-108450.md) | [(0.33)](/filings/0001193125-25-279086.md) | not reported | [0.13](/filings/0001193125-26-222904.md) | [(0.09)](/filings/0001193125-26-347980.md) | [(0.21)](/filings/0001193125-25-279086.md) | not reported | [(0.14)](/filings/0001193125-26-222904.md) | [(0.52)](/filings/0001193125-26-347980.md) |
| Basic EPS | $ per share | [(0.29)](/filings/0000950170-24-126767.md) | not reported | [(0.28)](/filings/0000950170-25-069833.md) | [(0.74)](/filings/0000950170-25-108450.md) | [(0.33)](/filings/0001193125-25-279086.md) | not reported | [0.15](/filings/0001193125-26-222904.md) | [(0.09)](/filings/0001193125-26-347980.md) | [(0.21)](/filings/0001193125-25-279086.md) | not reported | [(0.14)](/filings/0001193125-26-222904.md) | [(0.52)](/filings/0001193125-26-347980.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [43.0](/filings/0000950170-23-061566.md) | [35.4](/filings/0000950170-25-038803.md) | [25.7](/filings/0000950170-24-059118.md) | [21.5](/filings/0000950170-24-095784.md) | [16.6](/filings/0000950170-24-126767.md) | [103](/filings/0001193125-26-103134.md) | [92.2](/filings/0000950170-25-069833.md) | [101](/filings/0000950170-25-108450.md) | [87.0](/filings/0001193125-25-279086.md) | [120](/filings/0001193125-26-347980.md) | [195](/filings/0001193125-26-222904.md) | [202](/filings/0001193125-26-347980.md) |
| Current assets | $m | [45.1](/filings/0000950170-23-061566.md) | [36.8](/filings/0000950170-25-038803.md) | [27.1](/filings/0000950170-24-059118.md) | [22.7](/filings/0000950170-24-095784.md) | [18.1](/filings/0000950170-24-126767.md) | [104](/filings/0001193125-26-103134.md) | [93.1](/filings/0000950170-25-069833.md) | [104](/filings/0000950170-25-108450.md) | [90.1](/filings/0001193125-25-279086.md) | [121](/filings/0001193125-26-347980.md) | [198](/filings/0001193125-26-222904.md) | [204](/filings/0001193125-26-347980.md) |
| Total assets | $m | [50.1](/filings/0000950170-23-061566.md) | [41.2](/filings/0000950170-25-038803.md) | [31.2](/filings/0000950170-24-059118.md) | [26.5](/filings/0000950170-24-095784.md) | [21.5](/filings/0000950170-24-126767.md) | [107](/filings/0001193125-26-103134.md) | [95.9](/filings/0000950170-25-069833.md) | [106](/filings/0000950170-25-108450.md) | [93.6](/filings/0001193125-25-279086.md) | [125](/filings/0001193125-26-347980.md) | [202](/filings/0001193125-26-222904.md) | [208](/filings/0001193125-26-347980.md) |
| Current liabilities | $m | [10.3](/filings/0000950170-23-061566.md) | [14.2](/filings/0000950170-25-038803.md) | [13.5](/filings/0000950170-24-059118.md) | [14.0](/filings/0000950170-24-095784.md) | [15.3](/filings/0000950170-24-126767.md) | [37.5](/filings/0001193125-26-103134.md) | [20.1](/filings/0000950170-25-069833.md) | [14.7](/filings/0000950170-25-108450.md) | [10.9](/filings/0001193125-25-279086.md) | [9.0](/filings/0001193125-26-347980.md) | [7.1](/filings/0001193125-26-222904.md) | [12.7](/filings/0001193125-26-347980.md) |
| Total liabilities | $m | [27.0](/filings/0000950170-23-061566.md) | [28.5](/filings/0000950170-25-038803.md) | [25.2](/filings/0000950170-24-059118.md) | [36.5](/filings/0000950170-24-095784.md) | [36.8](/filings/0000950170-24-126767.md) | [40.5](/filings/0001193125-26-103134.md) | [21.2](/filings/0000950170-25-069833.md) | [15.8](/filings/0000950170-25-108450.md) | [13.5](/filings/0001193125-25-279086.md) | [73.3](/filings/0001193125-26-347980.md) | [63.9](/filings/0001193125-26-222904.md) | [82.0](/filings/0001193125-26-347980.md) |
| Long-term debt | $m | [14.3](/filings/0000950170-23-061566.md) | [11.6](/filings/0000950170-24-037637.md) | [9.2](/filings/0000950170-24-059118.md) | [6.7](/filings/0000950170-24-095784.md) | [4.2](/filings/0000950170-24-126767.md) | [1.7](/filings/0000950170-25-038803.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [6.1](/filings/0000950170-23-061566.md) | [8.9](/filings/0000950170-25-038803.md) | [9.8](/filings/0000950170-24-059118.md) | [9.8](/filings/0000950170-24-095784.md) | [9.9](/filings/0000950170-24-126767.md) | [9.9](/filings/0001193125-26-103134.md) | [9.2](/filings/0000950170-25-069833.md) | [6.7](/filings/0000950170-25-108450.md) | [4.2](/filings/0001193125-25-279086.md) | [0.0](/filings/0001193125-26-103134.md) | not reported | not reported |
| Shareholders' equity | $m | [23.0](/filings/0000950170-24-126767.md) | [12.7](/filings/0001193125-26-103134.md) | [6.0](/filings/0000950170-25-108450.md) | [(10.0)](/filings/0001193125-25-279086.md) | [(15.3)](/filings/0001193125-25-279086.md) | [66.3](/filings/0001193125-26-347980.md) | [74.7](/filings/0001193125-26-347980.md) | [90.2](/filings/0001193125-26-347980.md) | [80.1](/filings/0001193125-25-279086.md) | [51.9](/filings/0001193125-26-347980.md) | [138](/filings/0001193125-26-347980.md) | [126](/filings/0001193125-26-347980.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.8) d](/filings/0000950170-24-126767.md) | [(7.4) d](/filings/0000950170-25-038803.md) | [(8.4)](/filings/0000950170-25-069833.md) | [(6.2) d](/filings/0000950170-25-108450.md) | [(6.6) d](/filings/0001193125-25-279086.md) | [(5.8) d](/filings/0001193125-26-103134.md) | [(8.6)](/filings/0001193125-26-222904.md) | [(8.9) d](/filings/0001193125-26-347980.md) | [(10.2) d](/filings/0001193125-25-279086.md) | [(10.6) d](/filings/0001193125-26-103134.md) | [(18.0)](/filings/0001193125-26-222904.md) | [(17.2) d](/filings/0001193125-26-347980.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-126767.md) | [0.0 d](/filings/0000950170-25-038803.md) | [0.0](/filings/0000950170-25-069833.md) | [0.0 d](/filings/0000950170-25-108450.md) | [0.0 d](/filings/0001193125-25-279086.md) | [0.0 d](/filings/0001193125-26-103134.md) | [0.0](/filings/0001193125-26-222904.md) | [0.0 d](/filings/0001193125-26-347980.md) | [0.1 d](/filings/0001193125-25-279086.md) | [0.4 d](/filings/0001193125-26-103134.md) | [0.7](/filings/0001193125-26-222904.md) | [0.1 d](/filings/0001193125-26-347980.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [28.9](/filings/0000950170-23-061566.md) | [28.9](/filings/0000950170-24-059118.md) | [28.9](/filings/0000950170-24-095784.md) | [28.9](/filings/0000950170-24-126767.md) | [29.2](/filings/0000950170-25-069833.md) | [29.9](/filings/0000950170-25-108450.md) | [32.0](/filings/0001193125-25-279086.md) | [54.8](/filings/0001193125-26-222904.md) | [51.5](/filings/0001193125-26-347980.md) | [54.9](/filings/0001193125-25-279086.md) | [62.4](/filings/0001193125-26-222904.md) | [74.1](/filings/0001193125-26-347980.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 76,518,565 at 2026-08-06, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-347980.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.